Ghana Health Service (GHS): AstraZeneca is being pulled for business purposes.
The AstraZeneca Covid-19 vaccine has been withdrawn, according to the Ghana Health Service (GHS), for financial gain.
The manufacturers of AstraZeneca, a vaccine that was administered during the peak of the COVID-19 epidemic, have declared that they have begun a global vaccine withdrawal.
The multinational pharmaceutical company admitted to the presence of a rare side effect called Thrombosis with Thrombocytopenia Syndrome (TTS).
This disorder can cause symptoms including one-sided body numbness, chest pain, or unilateral limb pain and swelling. It is characterized by the production of blood clots that block veins or arteries.
Thrombosis-related consequences, such as heart attacks or strokes, can be fatal.
The business stated that the availability of more recent vaccines after the pandemic was the reason behind the withdrawal.
Speaking to reporters on Wednesday during a tour of the Ga East Municipality in Accra as part of the COVID-19 Vaccination and Child Health Promotion Week/African Vaccination Week Campaign, Ghana Health Service Director-General Dr. Patrick Kuma-Aboagye explained that the manufacturer’s withdrawal was motivated by competition rather than potential health risks.
“They are pulling out for business reasons because there are better vaccines available.”
“Therefore, why make something if you are in a market and cannot compete?
Thrombosis-related consequences, such as heart attacks or strokes, can be fatal.
The business stated that the availability of more recent vaccines after the pandemic was the reason behind the withdrawal.
Speaking to reporters on Wednesday during a tour of the Ga East Municipality in Accra as part of the COVID-19 Vaccination and Child Health Promotion Week/African Vaccination Week Campaign, Ghana Health Service Director-General Dr. Patrick Kuma-Aboagye explained that the manufacturer’s withdrawal was motivated by competition rather than potential health risks.
“They are pulling out for business reasons because there are better vaccines available.”
“Therefore, why make something if you are in a market and cannot compete?” he said.